These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38224415)

  • 21. Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory.
    Gurbel PA; Bliden K; Sherwood M; Taheri H; Tehrani B; Akbari M; Yazdani S; Asgar JA; Chaudhary R; Tantry US
    J Thromb Thrombolysis; 2024 Apr; 57(4):566-575. PubMed ID: 38480590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The contribution of genotype-guided selection of P2Y
    Wu Y; Yu D; Zhang L; Wu Y; Shu B; Ma L; Shi T
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1249-1259. PubMed ID: 37449992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective
    Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
    Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis.
    Xie Q; Xiang Q; Liu Z; Mu G; Zhou S; Zhang Z; Ma L; Gong Y; Jiang J; Cui Y
    BMC Cardiovasc Disord; 2022 Mar; 22(1):111. PubMed ID: 35300607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.
    Zhu KX; Song PY; He-Li ; Li MP; Du YX; Ma QL; Peng LM; Chen XP
    Eur J Clin Pharmacol; 2021 Mar; 77(3):359-368. PubMed ID: 33089397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Impact of CYP2C19 genotypes on antiplatelet therapy among Chinese patients with acute myocardial infarction after percutaneous coronary intervention].
    Xu JJ; Tang XF; Song Y; Xu N; Yao Y; Wu Y; Zhang J; Gao Z; Chen J; Gao RL; Yang YJ; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Feb; 45(2):116-120. PubMed ID: 28260316
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
    Cavallari LH; Franchi F; Rollini F; Been L; Rivas A; Agarwal M; Smith DM; Newsom K; Gong Y; Elsey AR; Starostik P; Johnson JA; Angiolillo DJ
    J Transl Med; 2018 Apr; 16(1):92. PubMed ID: 29642909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
    Johnson SG; Gruntowicz D; Chua T; Morlock RJ
    J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
    Gross L; Trenk D; Jacobshagen C; Krieg A; Gawaz M; Massberg S; Baylacher M; Aradi D; Stimpfle F; Hromek J; Vogelgesang A; Hadamitzky M; Sibbing D; Geisler T
    Thromb Haemost; 2018 Sep; 118(9):1656-1667. PubMed ID: 30103241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
    Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
    Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease.
    Cheng Y; Sun Y; Zhang D; Ma X; Liu C; Hu C; Sun T; Zhao Z; Liu X; Zhou Y
    Front Cardiovasc Med; 2023; 10():1105001. PubMed ID: 36760562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
    Jiang M; You JH
    Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y
    Pereira NL; Rihal C; Lennon R; Marcus G; Shrivastava S; Bell MR; So D; Geller N; Goodman SG; Hasan A; Lerman A; Rosenberg Y; Bailey K; Murad MH; Farkouh ME
    JACC Cardiovasc Interv; 2021 Apr; 14(7):739-750. PubMed ID: 33744207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.
    Barker CM; Murray SS; Teirstein PS; Kandzari DE; Topol EJ; Price MJ
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1001-7. PubMed ID: 20965456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
    Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
    Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.